NVP-AUY922 is an experimental drug candidate for the treatment of cancer. It was discovered through a collaboration between The Institute of Cancer Research and the pharmaceutical company Vernalis and licensed to Novartis. It is currently in Phase II clinical trials. NVP-AUY922 is an inhibitor of heat shock protein 90 (Hsp90), which is a chaperone protein that plays a role in the modification of a variety of proteins that have been implicated in oncogenesis. NVP-AUY922 has shown promising activity in preclinical testing against several different tumor types.
Sun-shinechem(SSC) provides a wide range of research chemicals and biochemicals including novel life-science reagents, reference compounds, APIs, building blocks and Natural compounds for laboratory and scientific use.